Does abnormal neuronal excitability exist in myotonic dystrophy? I. Effects of the antiarrhythmic drug hydroquinidine on slow saccadic eye movements

Neurological Sciences

Volumn 21, Issue 2, 2000, Pages 73-80

  Di Costanzo, A ^a   Mottola, A ^a   Toriello, A ^a   Di Iorio, G ^a   Tedeschi, G ^a   Bonavita, V ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Electrooculography; Myotonic dystrophy; Quinidine; Saccadic eye movements

Indexed keywords

ANTIARRHYTHMIC AGENT; DIHYDROQUINIDINE; QUINIDINE DERIVATIVE;

ADULT; AGED; APATHY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROOCULOGRAPHY; EPIGASTRIC PAIN; FEMALE; HUMAN; HYPERSOMNIA; MALE; MYOTONIC DYSTROPHY; NAUSEA; NERVE CELL EXCITABILITY; RANDOMIZED CONTROLLED TRIAL; SACCADIC EYE MOVEMENT;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOTONIC DYSTROPHY; NEURONS; QUINIDINE; SACCADES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033922392     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100720070099     Document Type: Article

References (41)

1. Harper PS, Rüdel R (1994) Myotonic dystrophy. In: Engel AG, Franzini-Armstrong C (eds) Myology. McGraw-Hill, New York, pp 1192-1219
2. Korade-Mirnics Ž, Babitzke P, Hoffman E (1998) Myotonic dystrophy: molecular windows on a complex ctiology. Nucleic Acids Res 26:1363-1368
3. Barchi RL (1998) Ion channel mutations affecting muscle and brain. Curr Opin Neurol 11:461-468
4. Timchenko L, Nastainczyk W, Schneider T, Patel B, Hofmann F, Caskey CT (1995) Full-length myotonin protein kinase (72 kDa) displays serine kinase activity. Proc Natl Acad Sci USA 92:5366-5370
5. Pham YCN, Man N, Lam LT, Morris GE (1998) Localization of myotonic dystrophy protein kinase in human and rabbit tissues using a new panel of monoclonal antibodies. Hum Mol Genet 7:1957-1965
6. Mounsey JP, Xu P, John JE III, Horne LT, Gilbert J, Roses AD, Moorman JR (1995) Modulation of skeletal muscle sodium channels by human myotonin protein kinase. J Clin Invest 95:2379-2384
7. 2+ homeostasis in skeletal muscle cells. J Clin Invest 100:1440-1447
8. Oliveri M, Brighina F, La Bua V, Aloisio A, Buffa D, Fierro B (1997) Magnetic stimulation study in patients with myotonic dystrophy. Electroencephalogr Clin Neurophysiol 105:297-301
9. Russo LS (1991) Altered motor neuron excitability in myotonic dystrophy. Electromyogr Clin Neurophysiol 31:461-466
10. Kwiecinski H, Ryniewicz B, Ostrzycki A (1992) Treatment of myotonia with antiarrhythmic drugs. Acta Neurol Scand 86:371-375
11. MacRobbie DS, Friedlander WJ (1957) Treatment of myotonia with procainamide. Arch Neurol Psychiatry 78:473-475
12. Rüdel R, Dengler R, Ricker K, Haass A, Emser W (1980) Improved therapy of myotonia with the lidocaine derivative tocainide. J Neurol 222:275-278
13. Mielke U, Haass A, Sen S, Schmidt W (1985) Antimyotonic therapy with tocainide under ECG control in the myotonic dystrophy of Curschmann-Steinert. J Neurol 232:271-274
14. Roses AD, Harper PS, Bossen EH (1979) Myotonic dystrophy. In: Vinken PJ, Bruyn GW, Ringel SP (eds) Handbook of clinical neurology. Diseases of muscles. Part I. Elsevier North-Holland Biomedical, Amsterdam, pp 485-532
15. Bungener C, Jouvent R, Delaporte C (1998) Psychopathological and emotional deficits in myotonic dystrophy. J Neurol Neurosurg Psychiatry 65:353-356
16. Chimienti M, Regazzi MB, La Rovere MT, Salerno JA, Previtali M, Montericcio V, Rondanelli R, Montemartini C (1988) Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration. Cardiovasc Drugs Ther 2:679-686
17. Roden DM (1996) Antiarrhythmic drugs. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A (eds) Goodman & Gilman's The pharmacological basis of therapeutics. McGraw-Hill, New York, pp 839-874
18. Glue P (1991)The pharmacology of saccadic eye movements. J Psychopharmacol 5:377-387
19. Di Costanzo A, Mottola A, Toriello A, Di Iorio G, Tedeschi G, Bonavita V (2000) Does abnormal neuronal excitability exist in myotonic dystrophy? II. Effects of the antiarrhythmic drug hydroquinidine on apathy and hypersomnia. Neurol Sci 21:81-86
20. Mathieu J, De Braekeleer M, Prévost C, Boily C (1992) Myotonic dystrophy: clinical assessment of muscular disability in an isolated population with presumed homogeneous mutation. Neurology 42:203-208
21. Marshall RW, Richens A (1989) An IBM-based system for the generation, collection and analysis of saccadic and smooth pursuit eye movements. Br J Clin Pharmacol 28:752P-753P
22. Baloh RW, Konrad HR, Sills AW, Honrubia V (1975) The saccade velocity test. Neurology 25:1071-1076
23. Lueck CJ, Crawford TJ, Hansen HC, Kennard C (1991) Increase in saccadic peak velocity with increased frequency of saccades in man. Vision Res 31:1439-1443
24. Torres C, Moxley RT, Griggs RC (1983) Quantitative testing of handgrip strength, myotonia, and fatigue in myotonic dystrophy. J Neurol Sci 59:157-168
25. Durelli L, Mutani R, Piredda S, Fassio F, Delsedime M (1983) The quantification of myotonia. A problem in the evaluation of new antimyotonic drugs. J Neurol Sci 59:167-173
26. Finlay M (1982) A comparative study of disopyramide and procainamide in the treatment of myotonia in myotonic dystrophy. J Neurol Neurosurg Psychiatry 45:461-463
27. Di Costanzo A, Toriello A, Mottola A, Di Iorio G, Bonavita V, Tedeschi G (1997) Relative sparing of extraocular muscles in myotonic dystrophy: an electrooculographic study. Acta Neurol Scand 95:158-163
28. Norman GR, Streiner DL (1994) Biostatistics. The bare essentials. Mosby-Year Book, St. Louis
29. Leigh RJ, Zee DS (1999) The neurology of eye movements. Oxford University. New York
30. ter Bruggen JP, Bastiaensen LAK, Tyssen CC, Gielen G (1990) Disorders of eye movement in myotonic dystrophy. Brain 113:463-473
31. Osanai R, Kinoshita M, Hirose K (1998) Saccadic slowing in myotonic dystrophy and CTG repeat expansion. J Neurol 245:674-680
32. Verhagen WIM, ter Bruggen JP, Huygen PLM (1992) Oculomotor, auditory, and vestibular responses in myotonic dystrophy. Arch Neurol 49:954-960
33. Hansen HC, Lueck CJ, Crawford TJ, Kennard C, Zangemeister WH (1993) Evidence for the occurrence of myotonia in the extraocular musculature in patients with dystrophia myotonica. Neuro-ophthalmology 13:17-24
34. Anastasopoulos D, Kimmig H, Mergner T, Psilas K (1996) Abnormalities of ocular motility in myotonic dystrophy. Brain 119:1923-1932
35. Emre M, Henn V (1985) Central eye movement disorder in a case of myotonic dystrophy. Neuro-ophthalmology 5:21-25
36. Shaunak S, Orrell R, Henderson L, Kennard C (1999) Saccades and smooth pursuit in myotonic dystrophy. J Neurol 246:600-606
37. Versino M, Romani A, Bergamaschi R, Callieco R, Scolari S, Poli R, Lanfranchi S, Sandrini G, Cosi V (1998) Eye movement abnormalities in myotonic dystrophy. Electroencephalogr Clin Neurophysiol 109:184-190
38. Roy-Byrne PP, Cowley DS, Radant A, Hommer D, Greenblatt DJ (1993) Benzodiazepine pharmacodynamics: utility of eye movement measures. Psychopharmacology 110:85-91
39. Tedeschi G, Bittencourt PRM, Smith AT, Richens A (1983) Effect of amphetamine on saccadic and smooth pursuit eye movements. Psychopharmacology 79:190-192
40. Hoffman BB, Lefkowitz RJ (1996) Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A (eds) Goodman & Gilman's The pharmacological basis of therapeutics. McGraw-Hill, New York, pp 199-248
41. Whiting EJ, Waring JD, Tamai K, Somerville MJ, Hincke M, Staines WA, Ikeda JE, Korneluk RG (1995) Characterization of myotonic dystrophy kinase (DMK) protein in human and rodent muscle and central nervous (issue. Hum Mol Genet 4:1063-1072